Antiviral Drugs Market is Expected to Experience a Swift Development by 2024

1
Disease Indication - Hepatitis Virus Infection,
HIV Infection, and Respiratory Virus Infection
Product Type - Branded Drugs and Generic Drugs
Distribution Channels - Hospital Pharmacy Store,
Retail Pharmacy Store, and Online
PharmacyForecast From 2016 - 2024
Antiviral Drugs Market
2
Table of Content
Sr. No. Content
Chapter 1 Preface
Chapter 2 Assumptions and Research Methodology
Chapter 3 Executive Summary
Chapter 4 Market Overview
Chapter 5 Global Antiviral Drugs Market Analysis and Forecasts, By Disease Indication
Chapter 6 Global Antiviral Drugs Market Analysis and Forecasts, by Distribution Channels
Chapter 7 Global Antiviral Drugs Market Analysis and Forecasts, by Region
Chapter 8 North America Antiviral Drugs Market Analysis and Forecast
Chapter 9 Europe Antiviral Drugs Market Analysis and Forecast
Chapter 10 Asia Pacific Antiviral Drugs Market Analysis and Forecast
Chapter 11 Latin America Antiviral Drugs Market Analysis and Forecast
Chapter 12 Middle East and Africa Antiviral Drugs Market Analysis and Forecast
Chapter 13 Competition Landscape 
3
 Antiviral Drugs Market Snapshot

• Antiviral drugs refer to those prescription
  medicines that are capable of fighting against
  flu viruses in ones body. Antiviral drugs could
  include intravenous solutions, an inhaled powder,
  liquid, or pills.
• Demand for new and improved targeted therapies
  for viral diseases continues to rise, primarily
  due to invention of broad spectrum antiviral
  drugs
• Global antiviral drugs market has been segmented
  on the basis of disease indication, product type,
  and distribution channels.

4
(No Transcript)
5
Reports Highlights

• Global anitiviral drugs market is projected to
  rise at a CAGR of 6.40 during the forecast
  period that is from 2016 and 2024. Rising at this
  CAGR, the antiviral drugs market is projected to
  clock a valuation of US82.9 bn by 2024.
• Key Players
• Merck Co. Inc., Johnson and Johnson,
  Schering-Plough Corporation, AbbVie Inc., and
  AstraZeneca Plc. among others.

Request Sample
6
(No Transcript)